中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.018 seconds)

    METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDS
    42.
    发明申请
    METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDS 审中-公开

    公开(公告)号：US20200088726A1

    公开(公告)日：2020-03-19

    申请号：US16569691

    申请日：2019-09-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Andreas MORITZ ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER

    IPC: G01N33/569 ,  C07K14/74 ,  A61K39/395 ,  A61K38/17

    Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

    DUAL SPECIFICITY POLYPEPTIDE MOLECULE
    43.
    发明申请
    DUAL SPECIFICITY POLYPEPTIDE MOLECULE 审中-公开

    公开(公告)号：US20190016802A1

    公开(公告)日：2019-01-17

    申请号：US16035412

    申请日：2018-07-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/28 ,  C07K16/10

    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    44.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 审中-公开

    公开(公告)号：US20170267738A1

    公开(公告)日：2017-09-21

    申请号：US15460654

    申请日：2017-03-16

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Dominik MAURER ,  Sebastian Bunk ,  Leonie Alten

    IPC: C07K14/725

    CPC classification number: C07K14/7051 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  A61K38/00 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

    Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    50.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230091330A1

    公开(公告)日：2023-03-23

    申请号：US17934303

    申请日：2022-09-22

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Patent Agency Ranking